Reliance on quantitative or financial methods of valuation make it very difficult to assess the real health of a biotech company because there are a number of non-numerical items to consider which rely more heavily on qualitative analysis as the more reliable method of valuing this type of company.
Investors who only use the common homespun simplicity of anecdotal evidence and first-hand observations may be quick to see why our market considers OBJ to be just another penny dreadful, but for any serious L/T investors who prefer to conduct rigorous research, and always do their homework wisely with a detailed examination of the company, and the global market landscapes it operates in, searching for what's 'NOT' only being promoted on the ASX capital raising notice platform will clearly show one the progressive fundamental strength of the company.
As the world's greatest investor, Peter Lynch famously said, "the market should only matter when you enter or exit a position; the rest of the time, it should be ignored. If you approach buying stocks like buying a business, you'll want to hold onto them as long as the fundamentals are strong."
As always, take every post with a grain of salt, including this one. Hotcopper is a great source of information when investors use it wisely. Information and opinions posted by others, without exception, should always be followed up by DYOR. The high level of secrecy between OBJ and its partners have made this company the most challenging I've researched, and speculating on the OBJ forum must always be treated as just that. By my own admission many research leads can veer off path which for many readers will invalidate an entire post - I have often said that with regards to research into OBJ shared on this forum, I believe that it is the sum of all things which must be understood, before gaining the confidence some of us have in this company and its management, and I also believe that this can only be appreciated by those who have done their own due diligence.
In regards to DYOR, I have also applied this rule with many ASX announcements from speculative companies, and to put it quite simply, the results of my own research in this regard have been highly disturbing. In regards to information released to the market from OBJ Limited, it should be reasonably clear to most researched investors that the board have taken a conservative approach since relationships have been formed with global partners, and I believe it would also be fair to say that this conservative style adopted by management has only intensified as the progression and additional interest received from more of the world's largest companies has increased. However, the company have not been free from its own hiccups and obstacles along the road, but imo where permitted management have always been prompt to inform the market of what the market may have considered to be "bad" news, but that all appears well behind us now, and I have found many critics, especially those in the media have continuely been proven wrong as more of this story behind the iron curtain of confidentiality unfolds. One of the major criticisms received from investors and analysts back in the early years was when the board first adopted its long term strategic development plan to target the big players for progressing further research and studies into its technologies, as this (I believe) derailed Jeff's original plan to commercialise the company's first product offerings during those early years, and of course the value of the company's securities were punished by the market for doing so. To some degree, where the current value has left large paper losses I can understand the disappointment of our long(er) termers, however when looking back and considering external events also witnessed after that period, such as the GFC, I believe the boards decision was both a wise one, with perhaps even a little 'luck' (given the events that did unfold during 2008). Over recent years as we have continued to see excellent progress with increasing global partnerships most criticism has been sp related, which has very little to do with the way a good business operates - I don't buy into the 'no promo' theme when a company is clearly involved in a high level of secrecy with its global partners - This only confirms that the market doesn't carry out much research, and from what I've been seeing with the major paradigm shifts going on around the world, most companies who are promoting their little hearts out today won't even be around in another 10 years time. In the marketing world we have not seen changes like this since World War II - Well before any of us working in this industry today were even born.
To those long(er) termers who are still invested in OBJ, I truly believe your patience will be very well rewarded, and your pay day is now fast approaching.
The presentation of this following keynote speaker has been posted on this forum before, however those invested in OBJ who have not watched this, I highly recommend that you do - Marc Pritchard is one of the most experienced leaders in the field of global brand buiding and marketing, and his role at the world's largest advertiser represents sales of over $80 billion dollars pa. There would be very few, if any, company in Australia that could ever afford to procure the services of this marketing guru for promoting its own products, however it is now becoming more and more apparent every day that this man will soon be marketing transformational new product innovations incorporating OBJ's technology platforms across multiple product categories, multiple brands and in a wide range of markets, and this is only one of the many qualitative items yet to be factored in by the market for measuring a more reliable value on OBJ Limited.
“P&G’s partnership with OBJ and our joint commitment of collaboration directly aligns with P&G’s business strategies, working to develop new solutions and innovations that can touch and improve the lives of our consumers all over the world,” - P&G Vice President of Global Business Development
The following list represents the essential items for consideration when conducting qualitative analysis as a method for putting a reliable value on a biotech company:
• Products and pipeline:
• Intellectual property:
• Research & Development:
• Senior management and other key staff:
• Partnerships:
• Financial Resources:
________________________________________
Products and Pipeline
A biotech company's product portfolio and research pipeline are the lifeblood of its success. That means you need to take a close look at the company's key products and the features of its technology. Ideally, the company should be developing a technology platform with multiple – rather than single – opportunities. Importantly, the company should be working on a large number of products that target large patient/consumer populations. Watch out for biotech firms developing products for big treatment or large volume areas – where potential return in investment is greatest. Stay clear of companies developing "me-too" products for areas that are already well served by existing technologies in the market. - Source
OBJ remains committed to its three-part commercial development strategy which focuses on partnering with major international pharmaceutical, cosmetic and FMCG companies, developing value added products and processes utilising OBJ’s proprietary design and development of its range of products to be distributed by channel partners.
The Company’s drug delivery platforms include powered electromagnetic delivery systems for use in devices and appliances, motion-activated magnetic micro-arrays for use in consumer products and devices and materials-based arrays for use in cosmetic and drug patch applications. The low-cost nature of these unique technologies along with their ease of use make these technologies uniquely suited to the pharmaceutical, consumer healthcare and cosmetic markets.
In 2012 OBJ expanded its current offers from its three core technology platforms listed below, with the addition of another three seperate technologies to suit a broad range of medical, household, and consumer needs.
eM-patch
A film based micro-array technology ideal for patches, masks, dressings and other topical applications. The magnetic micro-array film replaces the traditional plastic backing layer imparting new levels of product performance with minimal cost impact. The magnetic field gradients required to interact with each active ingredient and the barrier function of the target biology are programmed into the film during manufacture.
Field in Motion (FIM)
A magnetic micro-array film that is integrated into brushes, applicators and wipes captures the energy of motion of normal usage behaviour and redirects this to achieve new levels of product performance. Structures within the micro-array are developed to enhance delivery of active ingredients and to focus these at structures and pathways such as epidermal pores, follicles and dentine tubules. Well suited to brushes, scrubs, wipes, applicators and various products where consumer movement and manipulation from part of normal usage patterns.
Dermaportation
The technology generates a series of repeating quasi-rectangular waves of electromagnetic energy with peak maximum field strength of between 5 mT (milli Tesla) by a secure microprocessor smart technology with automatic Cyclic Redundancy Check (CRC) data integrity testing and systems integrity testing to ensure the quality and repeatability of the field characteristics. Designed for applications where repeat applications, extended usage and multi-formulation requirements make a powered reusable device the best solution. Able to be implemented as a power-patch, a wand, an instrument or an iPod-like device. Dermaportation is well suited to many professional and retail applications where repeat delivery of consumables or the targeted delivery of actives is beneficial.
LIPID AGGREGATION
The Dermaportation technique uses highly controlled patterns of low voltage energy. Rather than destroying the bilayer’s underlying structure, it is proposed that Dermaportation creates temporary constrainments within the lipid bilayers. While the precise methods used to achieve this are a matter of commercial confidentiality, this allows Dermaportation to create temporary regions of low probability densities, which manifest as ring-like voids surrounding a compacted lipid core, through which therapeutic drugs and compounds can readily pass. The Dermaportation technique is an analogue process where the size, sequence and duration of the generated voids are all controllable.
INDUCING THE DERMAPORTATION EFFECT
The Dermaportation process uses an induction technique as the mechanism for manipulating the stratum corneum lipid bilayers. This technique has a number of important practical and clinical benefits.
TARGETING
The inductive technique used allows Dermaportation to target accurately within 3 dimensions with no need for sophisticated targeting systems. The physical location of the inductive head in relation to the skin allows accurate and defined areas of action while frequency control allows Dermaportation to target the stratum corneum bilayers only, with little or no detectable effect in surrounding tissues.
CONTROL
Dermaportation provides a number of control functions, including void creation, void closure, induced compound mobilisation and controlled release. This allows Dermaportation to be used as a drug delivery protocol rather than a single process.
LOW ENERGY
The amount of energy produced by the Dermaportation system is approximately 1,000 times smaller than the stratum corneum lipid disruptive processes current used. This makes Dermaportation ideally suited to portability, out-patient and homecare usage.
NON-CONTACT
Dermaportation can operate through most non-conductive materials, including bandages, pads and cloths and functions without the requirement for physical contact. This avoids the traditional problems of allergies and burns often associated with contact pads.
PAINLESS
Dermaportation operates using a modality for which humans have no receptors. As a result, the effect is not detectible by the human body and is totally pain free and comfortable to use.
REGULATORY
Inductive processes have been used clinically throughout the world for over 40 years and are currently approved for human use in all major markets, including USA and Europe. The FDA approved the first inductive system in 1979.
CONCLUSION
Dermaportation is a Drug Delivery technology that provides an unprecedented level of dermal permeability control. The technology is powerful, yet gentle and represents the first of a new generation of bio-communication delivery systems. As such the market applications are enormous and the value of the technology to drug companies, medical professionals and patients/consumers will be considerable.
“The industry has been terrible at thinking outside the box, literally, the pill bottle.” – Christopher Seaton - SVP of Pharmaceutical Development, Bayer
Dermaportation - Case Applications
PAIN MANAGEMENT
The Intelligent Fentanyl Patch – Patient and computer controlled transdermal patch
Fentanyl is a powerful pain management drug, often used for postoperative pain in adults following major surgery. Current transdermal patches can maintain a steady level of drug over 72 hours, however if a patient experiences a sudden pain episode, there is no way to override these with simple patches. Dermaportation will offer intelligent patches, programmed to accommodate such very real demands but still function within doctor prescribed parameters. It will record patient usage to be programmable in the field and recorded for later examination. Intensive care with the freedom of home care. The capability to add sophisticated controls to the use of the transdermal patch will substantially increase the effectiveness of the delivery of pain management drugs and will allow the development of new drugs amenable to the new delivery parameters.
CHILDREN AS PATIENTS
Local Anaesthetic - Rapid drug delivery
Local anaesthetic gels and creams can take hours to be effective. Such products are commonly used in children to make injections and venepuncture more tolerable and to lessen the fear of injections. Emotional upset is common in children facing the prospect of an injection. Hastening the effect of local anaesthetic and other slow-to-act transdermal preparations has the potential to streamline a number of clinical processes and reduce the fear and upset for many pediatric patients.
Dermaportation has widespread application for the treatment of children.
TREATMENT OF SCARS
Surgery – Scar reduction and resolution
Scars both new and old are proving to be responsive to a number of therapies and processes designed to increase hydration. However, penetrating the scar tissues with therapeutic agents has been a major hurdle to the broad adoption of such therapies. Dermaportation has the properties and the molecular manipulation capabilities to hasten and enhance a number of acute and chronic scar reduction therapies. Dermaportation is uniquely suited to scar reduction as its small size and ease of use make it ideal for home-based and extended therapy scar resolution programs.
SKIN CANCER TREATMENT
Photodynamic Therapy – Rapid and effective uptake
Aminolaevulinic acid or ALA is currently gaining broad support for the non-invasive treatment of skin cancers (specifically superficial basal cell carcinoma) without scarring. The drug is applied to the skin (topically) for between 2 and 5 hours and is taken up by the lesion, which is then irradiated with light at 615nm for ten minutes. The ALA reacts to the light, changes its structure and destroys the cancer. Using Dermaportation, the time period for drug application would be shortened significantly and when combining with lignocaine the pain experienced by patients would also be eradicated. This overcomes both major disadvantages of this emerging treatment. Skin cancer rates are increasing with the damage to the earth’s ozone layer. The potential for a better and more rapid method of treatment promises to be a major area of opportunity for Dermaportation.
COSMETIC RESTORATION
Cosmetics – a new world of dermal restorative compounds.
The cosmetic world has been forced to rely on a relatively small number of simple and low molecular weight compounds in retail formulations, as the majority of more complex and larger compounds suffer from low absorption through the skin. Dermaportation is uniquely suited to the needs of both the retail and professional cosmetic industries. It creates temporary pathways through which these more active compounds can be introduced, without irritation or damage to the skin’s delicate structures. Many of the important matrix molecules, which once gave skin its youthful appearance are subject to sun damage, oxidation and biological degradation. Dermaportation will enable delivery of these compounds that induce important biological changes such as new collagen synthesis, manufacture of ground substance, angiogenesis, and thickening of the epidermis. By allowing these important compounds to be administered through-the-skin, Dermaportation will assist in the restoration of damaged skin to an improved state. The global market for improved cosmetic compound application is possibly the largest untapped market of all.
"Specifically the e-skin is potentially across all of OBJ’s technologies so we are not simply focusing on one specific area."
"Increasing numbers of patients, at a time when therapy costs are already high, puts strain on the management of disease in an often over-stretched system. Many delegates recognised that governments are beginning to view future treatments by outcome, in an attempt to find ways to reduce the overall cost burden. For example, agencies such as the National Institute for Health and Clinical Excellence (NICE) in the UK are pricing treatment options on just such a basis. Within this system, a number of drivers are being debated, including the trend towards home-based care to offset pressure on hospitals and local surgeries, and the efficiencies offered through better patient and outcome data management.
The move towards home-based care raises the prospect of more simplified drug delivery devices, based on two characteristics of this new market. The first is that the prescribers and carers may no longer be doctors, so instruction on use/training should be simple and effective. The second is that the patient themselves or their non-professional carer may be required to administer drugs previously given in a clinic, requiring simple and low-risk mechanisms to ensure safety and efficacy.
The advent of advanced drug delivery devices has arrived, raising the bar for many traditional devices. The companies that recognise this fact, and which focus their innovation accordingly over the next 10 years, will be rewarded with a growing market share by 2020, leading what will become a highly competitive and very lucrative industry. - Source
* The OBJ technology platform has recently also been extended beyond ETP and Dermaportation, and now includes a programmable applicator device, a new patent applied "popper" for single dose applications, and an integrated applicator combining magnetic array and microneedle technology.
The majority of OBJ’s potential partners, including the announced relationships with GSK, 3M, P&G and other Pharmacuetical and FMCG companies, have widely diversified product portfolios across multiple product categories and sectors. The potential for OBJ’s technology platforms to add value and product innovations across multiple product categories, multiple brands and in a wider range of markets has increased the appeal of the Company as a long term technology partner. The majority of current partnering discussions involve the adoption of the OBJ technology on a corporate platform, rather than a product by product basis
OBJ’s technologies are the first to meet the tough economic, environmental and usability needs of the wider consumer goods markets, featuring;
Economics
- Low cost, Good shelf-life, Single use or Re-usable
- Opportunity for reduced active levels
- Exhaustible reservoir potential
Adaptable Format
- Patches, strips, wipes, applicators, and devices
Active Compatibility
- Wide range of molecules and compounds (inc. peptides, nanoparticles)
- Chemically non-invasive
Engineered Delivery Profiles
- Release and Penetration Speed
- Overall delivery profile
- Depth of penetration
Intellectual Property
- Proprietary technology platform
- Opportunities for application specific patents.
________________________________________
Intellectual Property
A biotech company's technology and products might have great potential, but does the company possess patents to protect its technology? By giving the biotech company exclusive rights to its technology, patent protection increases the value of the technology and the company. The company can pursue R&D and commercial development with less fear of competitors "stealing" or infringing on their technology. Most importantly, patents can attract royalties-paying commercial partners with the financial clout to fund R&D, clinical trials, product development and marketing. - Source
Patent cliff
Patent cliffs' impact depends on many factors. The speed and degree of sales erosion when falling down patent cliff are not equal across countries, prescription setting, and therapy area and formulation type. On average, small molecule originals in the US witnessed the most severe sales erosion on patent expiry. In some countries, off-protection products don’t even get generic competition, particularly if the original’s sales are relatively small.
After the US, sales erosion due to patent cliff was next highest in the UK, Germany and France, and was the lowest in Australia, Italy, Russia, Spain and Japan. Originals did not see massive drops in sales upon patent expiry in China, since they often were exposed to generic competition from the outset.
2013 Global Life Sciences Outlook
OBJ offers a portfolio of proprietary technologies and supports partners by providing IP protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production. OBJ is the first company to develop low-cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.
* Dermaportation: Apparatus for facilitating transdermal delivery of therapeutic substances and method of transdermally delivering therapeutic substances
USA – Granted
EU - Moved to Allowance
PCT - Examiners Response
The invention claimed is:
1. An apparatus for facilitating transdermal delivery of therapeutic substances, said apparatus comprising: an electromagnetic field generating device including a coil which has electrical connectivity at both ends to allow unidirectional flow of current; a control device arranged to control said field generating device to alternately produce active and substantially inactive electromagnetic field portions, each said active electromagnetic field portion having a frequency of between 1 Hz and 100 Hz and comprising a plurality of generally rectangular electromagnetic field pulses wherein each electromagnetic field pulse has a duration of between 25 .mu.s and 100 ms, each said substantially inactive electromagnetic field portion including no electromagnetic field pulses, wherein the duration of the inactive electromagnetic field portion is longer than the duration of the active electromagnetic field portion.
2. Apparatus as claimed in claim 1, wherein the electromagnetic field generating device comprises a solid state switching device.
3. Apparatus as claimed in claim 2, wherein the control device is arranged to produce an energisation signal useable to control switching of the solid state switching device to produce active and substantially inactive energisation signal portions, each active energisation signal portion including a plurality of energisation signal pulses and a substantially inactive energisation signal portion including no energisation signal pulses, and wherein the active energisation signal portion produces the active electromagnetic field portion and the inactive energisation signal portion produces the inactive electromagnetic field portion.
4. Apparatus as claimed in claim 3, wherein the active energisation signal portion repeats at a frequency of between 10 Hz and 50 Hz.
5. Apparatus as claimed in claim 3, wherein each active energisation signal portion includes between 12 and 20 energisation signal pulses.
6. Apparatus as claimed in claim 2, wherein the solid state switching device comprises a transistor.
7. Apparatus as claimed in claim 1, wherein the control device comprises a microcontroller.
8. Apparatus as claimed in claim 7, wherein the microcontroller is programmable by a user so that an electromagnetic signal corresponding to a predetermined therapeutic substance delivery plan is produced.
9. Apparatus as claimed in claim 8, wherein the microcontroller is programmed such that dermal permeability is increased at one or more specific times.
10. Apparatus as claimed in claim 8, wherein the microcontroller is programmed such that dermal permeability is increased for a specific period of time.
11. Apparatus as claimed in claim 1, wherein the apparatus comprises a substantially flat member having the electromagnetic field generating device and the control device embedded therein.
12. Apparatus as claimed in claim 1, wherein the therapeutic substance is disposed on an outwardly facing surface of the apparatus.
13. Apparatus as claimed in claim 1, wherein the therapeutic substance is a drug, vaccine, ion, macromolecule, DNA fragment or gene.
14. The apparatus of claim 1, wherein the control device includes control circuitry arranged to control said field generating device to alternately produce said active and said substantially inactive electromagnetic field portions by selectively energizing and de-energizing said field generating device while power is applied to said control circuitry.
15. The apparatus of claim 1, wherein the electromagnetic field pulses have an electromagnetic field strength of less than or equal to 3 Gauss and sufficient to facilitate transdermal delivery of therapeutic substances by increasing dermal permeability of a portion of the skin of a user of the apparatus.
16. A method of transdermally delivering therapeutic substances, said method comprising: producing an electromagnetic field using a coil which has electrical connectivity at both ends to allow unidirectional flow of current; directing the electromagnetic field at a desired treatment area of a patient's skin; and controlling the electromagnetic field so as to alternately produce active and substantially inactive electromagnetic field portions, each said active electromagnetic field portion having a frequency of between 1 Hz and 100 Hz and comprising a plurality of generally rectangular electromagnetic field pulses wherein each electromagnetic field pulse has a duration of between 25 .mu.s and 100 ms, each said substantially inactive electromagnetic field portion including no electromagnetic field pulses, wherein the duration of the inactive electromagnetic field portion is longer than the duration of the active electromagnetic field portion.
17. A method as claimed in claim 16, wherein the step of controlling the electromagnetic field comprises producing an energisation signal useable to control switching of a solid state switching device to produce active and substantially inactive energisation signal portions, each energisation signal portion including a plurality of energisation signal pulses and a substantially inactive energisation signal portion including no energisation signal pulses and wherein the active energisation signal portion produces the active electromagnetic field portion and the inactive energisation signal portion produces the inactive electromagnetic field portion.
18. A method as claimed in claim 17, wherein the solid state switching device comprises a transistor.
19. A method as claimed in claim 17, wherein each active energisation signal portion includes between 12 and 20 energisation signal pulses.
20. A method as claimed in claim 16, wherein the control means comprises a microcontroller.
21. A method as claimed in claim 20, further comprising the step of programming the microcontroller so that during use an electromagnetic signal corresponding to a predetermined therapeutic substance delivery plan is produced.
22. A method as claimed in claim 21, further comprising the step of programming the microcontroller such that dermal permeability is increased at one or more specific times.
23. A method as claimed in claim 21, further comprising the step of programming the microcontroller such that dermal permeability is increased for a specific period of time.
24. A method as claimed in claim 16, wherein the active energisation signal portion repeats at a frequency of between 10 Hz and 50 Hz.
25. A method as claimed in claim 16, wherein the therapeutic substance is a drug, vaccine, ion, macromolecule, DNA fragment or gene.
26. The method of claim 16, wherein the electromagnetic field pulses have an electromagnetic field strength of less than or equal to 3 Gauss and sufficient to facilitate transdermal delivery of therapeutic substances by increasing dermal permeability of the desired treatment area of the patient's skin.
27. An apparatus for facilitating transdermal delivery of therapeutic substances, said apparatus comprising: an electromagnetic field generating device including a solid state switching device coupled to a coil which has electrical connectivity at both ends to allow unidirectional flow of current, the solid state switching device being operative to energize the coil with direct current to selectively produce an electromagnetic field; a control device coupled to the solid state switching device to control said field generating device to alternately produce active and substantially inactive electromagnetic field portions by selectively energizing the coil, each said active electromagnetic field portion having a frequency of between 1 Hz and 100 Hz and comprising a plurality of generally rectangularly-shaped electromagnetic field pulses wherein each electromagnetic field pulse has a duration of between 25 .mu.s and 100 ms, each said substantially inactive electromagnetic field portion including no electromagnetic field pulses, wherein the duration of the inactive electromagnetic field portion is longer than the duration of the active electromagnetic field portion.
28. The apparatus of claim 27, wherein the control device comprises a microcontroller programmable by a user so that an electromagnetic signal pattern corresponding to a predetermined therapeutic substance delivery plan is produced.
29. The apparatus of claim 27, wherein the electromagnetic field pulses have an electromagnetic field strength of less than or equal to 3 Gauss and sufficient to facilitate transdermal delivery of therapeutic substances by increasing dermal permeability of a portion of the skin of a user of the apparatus. - UPSTO Granted Dermaportation Patent
* Apparatus and method of treatment utilizing a varying electromagnetic energisation profile
PCT-Exam requested
* Method and apparatus for enhanced transdermal diffusion
European Patent Convention - Exam requested
Japan - Exam requested
USA - Filed
The invention claimed is:
1. A device adapted to deliver an active agent(s) or formulation including active agent(s) to a subject, said device comprising: (a) an anisotropic array of magnetic material wherein the magnetic fields generated by the magnetic materials are directionally offset such that the polarity of each field is counter to that of the adjacent field and each pair of fields are separated, at least in part, by an insulator; and (b) a thermal harnessing means for increasing kinetic energy in the active agent(s) or formulation including active agent(s).
2. A device adapted to deliver an active agent(s) or formulation including active agent(s) to a subject, said device comprising: (a) a biphasic array of magnetic materials wherein the magnetic fields generated by the magnetic materials are counter aligned such that the polarity of each field is counter that of the field adjacent to it and each pair of fields are separated by an insulator; and (b) a thermal harnessing means for increasing kinetic energy in the active agent(s) or formulation including active agent(s).
3. The device according to claim 1 wherein the device is secured to the subject by a wearable and thermally insulating occlusive dressing or patch.
4. A method of delivering an active agent(s) or a formulation including the active agent(s) to a patient comprising the step of: (a) locating said active agent(s) or formulation including active agent(s) between a device and the subject, wherein the device comprises an anisotropic array of magnetic material wherein the magnetic fields generated by the magnetic materials are offset such that the polarity of each field is counter to that of the adjacent field and each pair of fields is separated, at least in part, by an insulator and a thermal harnessing means for increasing kinetic energy in the active agent(s) or formulation including active agent(s).
5. A method of delivering an active agent(s) or a formulation including the active agent(s) to a patient comprising the step of: (a) locating said active agent(s) or formulation including active agent(s) between a device and the subject, wherein the device comprises a biphasic array of magnetic materials wherein the magnetic fields generated by the magnetic materials are counter aligned such that the polarity of each field is counter that of the field adjacent to it and each pair of fields are separated by an insulator and a thermal harnessing means for increasing kinetic energy in the active agent(s) or formulation including active agent(s).
6. A method of claim 4 wherein the device is secured to the subject by a wearable and thermally insulating occlusive dressing or patch.
7. The device according to claim 2 wherein the device is secured to the subject by a wearable and thermally insulating occlusive dressing or patch.
8. The device according to claim 5 wherein the device is secured to the subject by a wearable and thermally insulating occlusive dressing or patch. - Method and apparatus for enhanced transdermal diffusion
* Delivery Device
PCT Application Filed
* Delivery of Surface Care Products
PCT Application Filed
* Delivery of Skin Care Products
PCT Application filed
* Delivery of Hair Care Products
PCT Application filed
* Delivery of Oral Care Products
PCT -Application filed
* Delivery of Fabric Care Products
PCT Application filed
* Method and Device for Transdermal Delivery of Substances
Provisional Application - Filed
* A Device, System, Method , Computer Program And Data Signal For The Control Of A Transdermal Delivery Device
Provisional Applications - Filed
Edwards, Jeffrey D: UPSTO Patent Record Data
International Scientific Pty: EPO Patent Search
Edwards, Jeffrey D: EPO Patent Record Search
Patent applications should be organized and drafted with a long-term objective that carefully considers the multiple possibilities, and opportunities, of field-of-use licensing. This is particularly the case in the pharmaceutical, biochemical, and chemical disciplines, as inventions can have multiple applications that are sometimes impossible to foresee. Technology managers must, therefore, focus strategically, not only on the basic idea of an invention but broadly, in order to consider the various ways such an invention might be put into more widespread and more profitable use. Therefore, the more details, examples and alternatives that are thought through and then disclosed in the patent application, the greater the opportunity for future divisional or continuation applications, as well as future claims that can be exclusively (field-of-use) licensed. By making all of the institution’s licenses, in effect, field-of-use licenses, the technology manager retains the ability to take a possible future use and license it to someone else, maximizing the benefits of the inventions and generating higher royalties for the institution. - IP Handbook
2010
"Over the reporting period, the Company has expanded its Intellectual Property and Patent portfolios with the lodgement of seven new "Field of Use" patent applications covering the commercial areas of interest to OBJ's partner companies and the progression of its foundation patents through to examination in both the USA and Europe. These IP programs are designed to provide broad exclusivity across key markets and to allow efficient and effective licensing across key market sectors."
2011
"Over the period, the Company has undertaken significant expansion to its IP and Patent portfolios with the lodgement of 6 additional "Field of Use" patent applications covering the major commercial areas of interest to OBJ's partner companies and the progression of its foundation patents through to final examination in both the USA and Europe. These programs are designed to provide OBJ with broad exclusivity across key markets and to allow efficient and effective licensing across key market sectors.
2012
"There is mounting international pressure in the pharmaceutical sector to control the dose of topical products, especially those containing non-steroid anti inflammatory compounds. As these drugs are a good target for our magnetic micro-array technologies, the Company moved to develop and file patents for a number of new enhanced delivery measured dose devices. Two such product groups are under development and the Company has received strong interests from its current partners."
2012
"The Company has been working with the University of Queensland and in particular Dr Tarl Prow in the development of enhancing micro-needle performance with the addition of OBJ’s ETP magnetic technology. OBJ’s ETP technology, when integrated into a traditional micro needle delivery system, showed substantially greater drug delivery than micro-needles alone. The resulting technology was the subject of a recent patent application and the results of that work were presented at the PPP Drug delivery Conference in France early in the month by OBJ Director, Dr Chris Quirk."
________________________________________
Research & Development
Does the company have a track record of productive research and development? Mature biotech companies spend about a fifth of total revenue on R&D, while early-stage biotech ventures typically spend well in excess of hundred percent of revenues on R&D. Not surprisingly, the outcome of R&D spending can vary wildly, especially for early stage biotech ventures. A key factor in success is the ability to develop cost-effective technologies that represent breakthrough products. R&D that delivers similar results to those already on the market is less likely to translate into successful products. Look for companies with R&D programs focused on diseases that aren't currently well-treated. - Source
"Reduces Transdermal Drug Delivery Times by 70%"
"Demonstrates fine control over drug delivery rates"
"Accelerates Skin Cancer Drug Absorption by 900%"
"Vaccine Patch Matches Injections in 2nd Phase Pilot Study"
"OBJ's Technology Enhances Follicle Drug Delivery"
"Reduces Time to Onset in Successful Clinical Trial"
"Positive Results for Delivery of Therapeutic Peptide"
"Pfizer - GLANVAC Sucessful Vaccine Study"
"100 fold increase for TDD of NALTREXONE"
"75 fold increase in CORTISONE"
"TDD technology proven in HUMAN TRIAL"
"OBJ demonstrates lasting effects of the hormone ESTRADIOL"
"Successful human clinical trial of Smith & Nephews AMETOP"
"POSITIVE RESULTS FOR DELIVERY OF THERAPEUTIC PEPTIDE"
"eM-PATCH® DELIVERS SIGNIFICANT IMPROVEMENT IN TOOTH" WHITENING
"The developed patch system effectively fluxes approximately a 10-fold over the existing product comparatively.”
"OBJ and GlaxoSmithKline Consumer Healthcare have entered into an exclusive Collaborative Development Agreement with the objective of developing new consumer products..."
"GSK and OBJ have collaborated on enhanced oral healthcare developments on similar bases resulting in statistically and commercially significant levels of enhancement."
"Amongst recent successes has been an independent university study that showed a significant increase in the delivery of a key anti-ageing ingredient..."
"The ability to show enhanced penetration of cosmetic compounds beyond the superficial surface provides a major competitive advantage for cosmetic and FMCG companies."
"Success in multiple ex-vivo studies under the GSK Collaboration Agreement led to the first-in-mouth studies in humans during 2012. Successes in this work and in other ingredient Proof of Concept (POC) studies has led to an expansion of the current Oral health development program."
"Success in initial ex-vivo feasibility studies using specific GSK formulations led to a formal Feasibility Testing program during 2012. Success in that activity has resulted in discussions regarding a further development stage study."
"The success of the pre-clinical developments has enabled the two companies to finalise the design, format and protocols for two important human clinical trials aimed to start in early 2013."
A key factor in success is the ability to develop cost-effective technologies that represent breakthrough products. R&D that delivers similar results to those already on the market is less likely to translate into successful products.
Some International Presentations:
Dermaportation treated skin is more permeable to Voltaren Emulgel at World Congress on Inflammation, Copenhagen.
Increased transdermal delivery of local anaesthetics by the novel penetration enhancement technology Dermaportation - Pharmaceutical Science World Congress in Amsterdam.
Enhanced transdermal delivery of a dipeptide by Dermaportation - 4th International Peptide Symposium, Cairns, Qld.
Enhanced transdermal delivery of a dipeptide by inductive energy - PPP Conference, La Grande Motte, France
Electromagnetophoresis - 3rd Symposium and Skin Forum 10th Conference, Versailles, France
Electromagnetic field energy as a skin penetration enhancer - Australasian Pharmaceutical Science Association Conference, Hobart, Tasmania.
Magnetic enhanced transdermal drug delivery - PPP Conference, La Grande Motte, France
European Bio-Partnering Conference - London, England
Enhanced microneedle delivery by magnetic microarrays - PPP Conference, La Grande Motte, France
Links to some Peer Reviewed articles
Journal of Chromatography
Liquid chromatography assay for 5-aminolevulinic acid: application to in vitro assessment of skin penetration via Dermaportation.
Biopolymers
Enhanced transdermal delivery of a dipeptide by dermaportation
Journal of Pharmacy and Pharmacology
Enhanced skin permeation and hydration by magnetic field array
Journal of Pharmaceutical Science
Enhanced Skin Permeation of Naltrexone by Pulsed
Electromagnetic Fields in Human Skin
Links to some Presentations not announced to the market
eM-Patch Cosmetic Presentation
Technical Presentation
Corporate Presentation - 2011
AGM Presentation - 2012
I would propose that a key factor in successful R&D is also having the ability to develop cost-effective disruptive innovation that represents breakthrough products, and what better way for any JDA partner of disruptive innovation to learn about the consumer, than by getting up close and personal...
This was first covered in "Will Disruptive Innovations Cure Health Care" by Clayton Christensen, Richard Bohmer, and John Kenagy in the September-October 2000 issue of Harvard Business Review.
The article describes how disruptive innovations have come to come in line with other industries, and would inevitably come to health care. Simpler, lower cost options for meeting patients' simpler needs would get a foothold in a market, and then take more and more market share.
One needs to look no further than OBJ's Joint Development Partner...
P&G Plots Growth Path Through Services
Mr. McDonald said service is "part of our broader purpose," noting, "It's fair game for us, and we need to learn more about it. We've got to grow; that's the main thing." While being big has the drawback of requiring big numbers to generate growth, he said, it also means P&G can afford to "place some bets that might not be so obvious from the outside."
One of those is MDVIP, a concierge-physician service that provides premium hour long physicals, electronic medical records on a CD, personal websites and preventive-care plans.
"If you're serious about being in the health-care business, what better learning lab is there than a concierge medical practice where you learn about everybody's aches and pains, and you work on developing the future of medicine, which is consumer choice and prevention rather than cure?" Mr. McDonald said.
For anyone curious to know what relevance MDVIP has with doing qualitative analysis on OBJ - For our JDA partner, P&G, this is where the research work for developing the future of preventative medicine begins... With over 500 of the top physicians in the US, and over 180,000 patients, what more resourceful research setting could any company wish for?
________________________________________
Management and Key Personel
Talent and experience of management is critical for long term success. Ideally, the biotech company should be run by executives who have developed and commercialized treatments before. It's a good idea to look for management teams with a track record of meeting publicly-stated goals and development milestones. Meanwhile, be wary of companies that regularly miss their targets. Executives must have an excellent understanding of the clinical and commercial development process, appreciate the costs involved, and have a record of putting company's resources into projects that offer high returns on investment. - Source
Mr Jeffrey Edwards - Executive Director
Jeffrey Edwards has over 20 years experience in managing new technological innovations. He is experienced in production, intellectual property, regulatory affairs and quality systems. He is an award winning technology developer, and has worked with a number of leading international technology companies, including IBM and NCR, and medical and biomedical companies, including Global Energy Medicine and CollTech. During the past three years, Mr Edwards has not held a directorship in any other listed companies.
Mr Glyn Denison - Non Executive Director
Glyn Denison is a qualified professional engineer and operates his own business consultancy advising companies in their development internationally. Mr Denison was one of the founders of the ERG Group and held several senior executive positions over the period from 1987 to 2003. These positions included President of the Americas for the ERG fare collection business and the New Business Development Director for ERG Transit. Prior to ERG, Mr Denison held several commercial positions with Bunnings Forest Products (now part of the Wesfarmers Group).
Dr Christopher Quirk - Non Executive Director
Christopher Quirk is an Australian dermatologist who has been a teaching hospital consultant for 27 years and has conducted numerous trials for international pharmaceutical companies such as Roche, Novartis, 3M and Matrix and has served on advisory boards for Abbott, Wyeth (Pfizer), Janssen (Johnson & Johnson), Merck, Allergan and Roche. He has published 22 papers in international journals and has presented at the World Congress of Dermatology and the World Congress on Cancers of the Skin.
Dr. Kevin Hammond - International Partnering Manager
Dr Hammond has over 30 years experience with some of the world’s leading pharmaceutical, FMCG and cosmetic companies. His principal responsibilities have involved managing the partnering, licensing and new product innovations for companies such as Reckitt Benckiser, Unilever, PZ Cussons, CB Fleet (US) and GSK. Dr Hammond’s wealth of experience in new technology applications and technology acquisition for major industry leading companies provides a unique insight into commercial partnering and licensing opportunities with potential partners. Dr Hammond holds a PhD in Physical Biochemistry, a B.Sc. in Biochemistry and is a member of the Editorial Board of the International Journal of Cosmetic Science.
Dr Matthew McIldowie - Senior Research Manager
Dr. McIldowie is a bio chemist who leads the Company’s product research programs in both the biological and non-biological areas. Dr. McIldowie has building OBJ's research teams to work alongside partnering companies
Dr Heather Benson - (Senior Scientific Advisor)
Dr Benson has extensive experience in drug delivery with particular focus in transdermal and topical delivery. She is an Associate Professor at Curtin University in Perth, where she leads the Drug Delivery Research Group. Prior to Perth Dr Benson was at the University of Manitoba in Canada where she was awarded Innovation funds to establish the Transdermal Research Facility. She also established the highly successful topical and transdermal research group at the University of Queensland. She has published extensively on her research and has supervised numerous Masters and PhD's in drug delivery research areas. She is on the editorial board of Current Drug Delivery and acts as a reviewer for many journals. Heather is a member of the CRS Australian Chapter Executive Committee, the Australian Peptide Society Conference Organising Committee, and the author of Topical and Transdermal Drug Delivery: Principles and Practice published in 2012
OBJ’s portfolio of key international experts to support core programs has been further extended to meet partnering needs and we have continued to engage academic institutions in supporting our research programs. This outsourcing beyond OBJ core capabilities has not only increased the pace of development activities but has also reinforced our credibility with partners and elevated the OBJ profile in the wider marketplace.
________________________________________
Partnerships
These days, biotech companies can rarely succeed alone. Given the big costs of drug and technology development, a biotech company will be held back from reaching its full potential unless it can find partners to help fund clinical trials and commercialization. So, it's important to find out if the company has secured promising collaborations and licensing partnerships. Look for partners that show lasting commitment – remember, the biotech product development process can be a very long and expensive one. Also, keep an eye on deal terms as they offer a reliable indication of value that the market gives to the technology. A good licensing partnership agreement will include not only a generous royalty rate on future sales but also healthy upfront payments plus milestone payments for achieving development targets. - Source
For the long term investors among us, it is this part of a qualitative analysis which provides all the evidence of a market which really doesn't have much idea on how to measure the value of a company in this sector. I can't even bring myself to use the term, "IMO" at the end of such a statement as I feel that would only be insulting to any half intelligent child - Imo, perhaps the world is also round!
Not only is early research activity for a small biotech company's own technology platforms being fully funded by global partners often a rare occurrence to the scale we witness with OBJ partnership funding, but for a small biotech company to be in a position to specifically, and strategically target whichever global partners it wishes to work with, and fund its programs, is a significant endorsement for the company's technology platforms.
3M
- Global sales: $27 billion
- International (non-US) sales: $17.5 billion (65 per cent of company's total)
- Operations in more than 65 countries
- 3M products sold in nearly 200 countries
- 80,000 employees globally
What makes 3M somewhat unique to OBJ's other global partners is that 3M were the only company that have not been targeted by OBJ. 3M first approached OBJ, although I'm not sure about the specifics surrounding the initial approach by 3M, the market have since been informed that 3M will be the contract manufacturer for magnetic arrays to OBJ's partnering companies, and would continue to explore new opportunities together in the pharmaceutical, consumer and consumer healthcare fields.
"In the case you have stated, it is quite common for 3M to be paid to evaluate the pharmacokinetics of any drug in a 3M patch adhesive system. This may be sufficiently promising for a Phase 1 clinical trial to take place. This process is not normally commercially sensitive. 3M is primarily a contract manufacturer so works with many different drug companies to further those companies’ compounds.
OBJ works with quite a different model. OBJ works with major international pharmaceutical and FMCG companies to help them develop new products. This is highly secretive work as these are highly competitive sectors, so our partners rarely permit us to announce our progress, as that would alert competitors to where these majors are focusing their product development plans." - Glyn Denison
In regards to 3M's relationship with OBJ we only know that, "3M remains a Major collaborator with OBJ"
3M Innovation
3M Drug Delivery Systems
3M Transdermal and Microneedle Posters, Presentations & Publications
3M Micro-needle Technology
3M Passive Transdermal Technology
3M CoTran™ Membranes
3M Electronics Design & Manufacturing
GlaxoSmithKline
GSK employs over 90,000 people worldwide including over 40,000 in sales and marketing. Its global headquarters are GSK House in Brentford, United Kingdom, with its United States headquarters based in Research Triangle Park (RTP) in North Carolina and its consumer products division based in the Pittsburgh suburb of Moon Township, Pennsylvania. The research and development division has major headquarters in South East England, Philadelphia and Research Triangle Park (RTP) in North Carolina. The single largest market is in the United States (approximately 45% of revenue), although the company has a presence in almost 70 countries. In November 2009 GlaxoSmithKline formed a joint venture with Pfizer to create ViiV Healthcare. Viiv Healthcare received all of Pfizer and GlaxoSmithKline's HIV assets. ViiV Healthcare is 85% owned by GlaxoSmithKline and 15% owned by Pfizer.
GSK Consumer Healthcare (UK)
GSKCH medicines and vaccines in development are classified into three stages: Phase I, Phase II and Phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval. This page provides an outline of the medicines and vaccines in development. The content of our development pipeline will change over time as new compounds progress from discovery to development and from development to the market. An update will be available in March 2013. For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.
GlaxoSmithKline Pharmaceuticals (US)
North America Pharmaceuticals
We are interested in marketed products and assets in late stage development. Your products will benefit from our in-depth understanding of patients, providers and payers and will benefit from our extensive marketing, sales and market access expertise.
Areas of specific interest are primary care, hospital and specialty products, in the following areas:
* cardiovascular
* metabolic
* neurosciences
* respiratory
* urology
* dermatology (through our skin care specialist company Stiefel)
* immunology
* oncology
* vaccines
However, we are open to discussing opportunities in other areas as well. In addition, we are open to exploring innovative collaboration options in Canada using our capabilities to help you build your own presence or pursue a "go it alone" strategy.
Innovation and investment
How does a pharmaceutical company ensure that it has a steady supply of great ideas and brilliant science in the earliest stages of discovering new medicines? Our approach is to make the most of the expertise we have in-house, and at the same time look outside for the best science, no matter where it might be.
By creating networks outside the company and collaborating with partners in academia, industry and government, we’re able to bring the best minds together and share expertise, which encourages innovation and stimulates entrepreneurship.
Another source of new technologies and transformative medicines is small start-ups and biotechnology companies that may eventually become GSK partners. But with recent challenges in the economic environment, many emerging biotechs - who rely on venture capital - have had a hard time raising the funding they need.
We believe that a thriving biotech sector is crucial for the success of the entire pharmaceutical industry, and we are committed to supporting and nurturing start-ups and encouraging entrepreneurship and innovation.
Here are a few of the novel approaches we have taken to do that:
* Announced the launch of the GSK Canada Life Sciences Innovation Fund, a new national $50 million fund that will significantly advance the commercialisation of scientific innovation in Canada by investing in early stage breakthrough research. The fund will identify strategic investment opportunities within Canada’s life sciences industry, including academic and health institutions, translational research centres, and start-up companies.
* Joined forces with competitor Johnson & Johnson to launch Index Ventures’ first fund, solely dedicated to making investments in the life sciences sector. This unique pharma/venture partnership model is intended to stimulate promising, early-stage R&D innovation.
* We have our own independent corporate venture firm, SR One, one of the first established in the US and now with offices in the UK also. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Its current portfolio includes approximately 30 private and public companies, and since its founding in 1985 it has invested over $680MM in the biotech field.
* Our R&D-based Scinovo team has a unique scientific support model, providing potential and existing partners an opportunity to access our drug discovery and development knowledge and expertise. As a dedicated team, Scinovo consultants can draw upon the breadth and depth of their experience to provide targeted and integrated solutions that help our collaborators navigate the development landscape, while also providing access to other experts within GSK where specialist knowledge is required.
* The Centre of Excellence in External Drug Discovery (ceedd) is another GSK group that is focused on finding the best science and innovation from outside the company. Its small, multidisciplinary team was established in 2005 and pioneered the quest to find innovation outside GSK, going to great lengths to actively seek out and collaborate with world-class biotechnology companies. Over the last six years the ceedd has built alliances with more than 10 companies and has brought four assets at proof of concept into GSK for further development.
Consumer Healthcare collaborations
Our Consumer Healthcare business has four global categories: Oral Health, Skin Health, Wellness/ Over-The-Counter (OTC) and Nutrition. Each is supported by a dedicated Business Development team. We are interested in external opportunities at both a global and regional level (especially in Emerging Markets), to help deliver growth for the business by harnessing scientific innovation to support our global and regional brands.
Our areas of interest
We are keen to explore potential collaboration opportunities - on a flexible and creative basis - and reach agreements that make sense for both sides including:
* acquisition of brands or companies
* in-licensing of technology or finished products
* any other types of collaborations that will enable further growth
Key areas of interest for each of our global categories are:
* Oral Health: sensitivity and acid erosion, denture care, gum health, dry mouth and family oral healthcare
* Skin Health: dry skin, clean and blemish free, ageless, sun care and lip care
* Wellness: pain management, respiratory health, gastro-intestinal and smoking reduction and cessation
* Nutrition: family nutrition, functional beverages and adult specialist nutrition
How we evaluate partnering opportunities
We will review all opportunities against our strategic areas of interest and communicate, openly and promptly, our level of interest to you as a prospective collaborator and/or alliance partner. Aside from commercial factors, we will only market or consider a product for launch if it has a strong scientific foundation.
We are keen to build long-term and enduring relationships throughout the deal process and thereafter. - Consumer Healthcare collaborations
Vaccines collaborations
Pharmaceutical collaborations
GSK Net Sales 2011
Pharmaceuticals £18.7 billion
Vaccines £3.5 billion
Consumer Healthcare OTC £2.5 billion
Oral healthcare £1.7 billion
Nutritional healthcare £1.0 billion
"Sensodyne Repair & Protect, a strong contributor to growth in the Consumer Healthcare business, is the first everyday fluoride toothpaste to contain NovaMin technology, which is proven to repair sensitive teeth. Since its launch in February 2011, Sensodyne Repair & Protect has been available in 30 markets across Europe, Asia and the Middle East, with 20 additional launches planned for 2012. The Sensodyne franchise has registered double-digit growth for 11 consecutive quarters."
In May 2010 this article first appeared about a small struggling biotech company which struck up a deal with GSK worth $135 million dollars for the NovaMin technology. GSK was keeping the deal confidential, but word slowly started leaking out in the local biotech community after the acquisition was mentioned in the company's 2009 annual report. A GSK spokeswoman would only confirm at the time that the deal was completed in December 2009.
Perhaps this allows one to consider what value GSK might place on new platform technologies which can significantly enhance the performance of GSK Oral Care products, and additionally what role confidentiality might play for GSK in regards to protecting new innovation in this fast moving competitive consumer world?
Next generation delivery technologies for enhancing product performance as well as reducing chemicals which in turn reduces GSK's chemical footprint, lowering production costs and increasing GSK's profit margins.
The Aquafresh Science Academy
Innovation GSK
GSK Dental Science
The Procter & Gamble Company
P&G is the world’s largest and most profitable consumer packaged goods company, with nearly $84 billion in sales and more than $10 billion in net earnings. They have built a portfolio of 25 billion-dollar brands — each of which generates from $1 billion to more than $10 billion of sales per year. They span a broad range of product categories — including household care, beauty, grooming, and personal health care — and are household names around the world. P&G have three times more billion-dollar brands in its product categories than its next-largest competitor and more than most of P&G's remaining competitors combined. - P&G - 2012 Annual Report
P&G Beauty & Grooming
P&G - Science in the Box
Sustainability: What the
consumer products industry expects of the chemical industry
P&G are also the world's largest marketing company, and the following video presentations from P&G's Global Marketing Manager, Marc Pritchard explaining some of the new rules for a consumer driven successful brand building in the new digital world:
"Late in 2011, the Company reported that the previously announced Strategic Alliance program with one of the world's leading Consumer Products companies had further progressed following successful technical evaluations. In October, the Company learned that the FMCG company was seeking world-wide exclusive access rights to OBJ’s technologies in the area of a beauty. Negotiations commenced regarding the various financial, developmental and investment commitments by the FMCG company to OBJ’s technologies and considerable progress in these negotiations was achieved during the period."
"The US granted patent for the Dermaportation or powered technology device has subsequently resulted in considerable interest from major cosmetic groups for the Company’s new e-skin product range. The potential market exclusivity provided by the US patent has considerably strengthened market interest."
Two weeks ago OBJ advised, "that it has received notification from its patent attorney that the European patent application protecting the Company’s powered electromagnetic drug and cosmetic delivery technology “Dermaportation”, has proceeded to Allowance. The US Patent Office granted this same patent Allowance for “Dermaportation” to OBJ in November of 2011.
We are advised that formal granting of the patent normally occurs in approximately 3 to 6 months. Dermaportation was the Company’s first drug delivery technology and has recently been incorporated into the e-Skin® cosmetic device system which is the subject of commercial discussions with a global skin care company."
OBJ's progress with the P&G collaboration and JDA appears to be moving at a good pace across multiple fronts - Imo, it's quite difficult to see material/commercial deals with our P&G strategic alliance program escaping 2013. I continue to believe that our EPO Dermaportation patent grant remains a key feature in current commercial negotiations.
Strategic Alliance with Global FMCG Company
Global FMCG Company to Secure Access Rights for Beauty Care
Procter and Gamble Enters Joint Development Agreement
P&G Progresses to Clinical Trials
With the exception of The Procter & Gamble Company and GSK, where permission has been granted for certain Shareholder updates, the specific names of some of the major partners to OBJ in certain markets remain undisclosed at this time, with references only being provided for their global market positions:
During 2012 OBJ Limited became a Technology Partner to the following companies:
• World’s largest Consumer Products Company
• World’s largest Pharmaceutical Company
• World’s second largest Oral Healthcare Company
• Top 5 Global Prestige Cosmetics Company
• Top 10 Global Prestige Skincare Company
The names of Pfizer and Samsung Electronics as technology partners to OBJ Limited are based on speculation only
• World’s largest Consumer Products Company
Samsung Electronics Company Ltd
Samsung Electronics is also the world's largest mobile phone maker by 2011 unit sales and world's second-largest semiconductor chip maker by 2011 revenues (after Intel Corporation). It has been the world's largest television manufacturer since 2006 and the world's largest maker of LCD panels for eight consecutive years. It has the largest marketshare worldwide in memory chips. The company was the world's largest vendor of smartphones in 2011. Samsung has also established a prominent position in the tablet computer market, with the release of the Android-powered Samsung Galaxy Tab. - Samsung Electronics - From Wikipedia
* OLED Display:
By 2004 Samsung was the world's-largest manufacturer of OLEDs, with a 40 percent market share worldwide, and as of 2010 has a 98% share of the global AMOLED market. The company is leading the world OLED industry, generating $100.2 million out of the total $475 million revenues in the global OLED market in 2006. As of 2006, it held more than 600 American patents and more than 2,800 international patents, making it the largest owner of AMOLED technology patents. Samsung's latest AMOLED smartphones use its Super AMOLED trademark, with the Samsung Wave S8500 and Samsung i9000 Galaxy S being launched in June 2010. In January 2011, it announced its Super AMOLED Plus displays – which offer several advances over the older Super AMOLED displays – real stripe matrix (50 percent more sub pixels), thinner form factor, brighter image and an 18 percent reduction in energy consumption. - Samsung Electronics - From Wikipedia
* Samsung Medical Center
Samsung donates around US$100 million per annum to the Samsung Medical Center. Samsung Medical Center incorporates Samsung Seoul Hospital, Kangbook Samsung Hospital, Samsung Changwon Hospital, Samsung Cancer Center and Samsung Life Sciences Research Center. Samsung Cancer Center, located in Seoul, is the largest cancer center in Asia. Samsung Medical Center and the multinational pharmaceuticals company Pfizer have agreed to collaborate on research to identify the genomic mechanisms responsible for clinical outcomes in hepatocellular carcinoma - Samsung Electronics - From Wikipedia
The World's Top 50 Consumer Products Companies
• World’s largest Pharmaceutical Company
Pfizer Inc
From my OBJ 2012 - qualitative analysis posted at the beginning of the year:
"As listed in the 2011 AGM Presentation OBJ not only advised of a global FMCG company progressing to multiple products and the GSK development collaboration moved to human studies and another UK FMCG company had commenced consumer testing of a patch product but they also advised of multi-product discussions commencing with a major US Pharmaceutical company. Although similar disclaimers are made by many of the big Pharma's the following is provided in this Pfizer Pipeline Presentation released last week: "As some programs are still confidential, some candidates may not be identified in this list. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities."
For those interested here is the most recent Pfizer Pipeline Presentation - November 2012
• World’s second largest Oral Healthcare Company
Crest and Oral-B Pro Health
I continue to speculate that there may be a possible coopetition in play here with the potential of both P&G and GSK Consumer Healthcare sharing technology partner innovations in taking on the World's Largest Oral Healthcare Company, Colgate.
Both P&G and GSKCH each being given the title of, World’s second largest Oral Healthcare Company through different research companies only fuels the speculation, and interestingly, on page 3 of this P&G Dental Care website flyer GSK's #1 selling Oral Health brand, Aquafresh is also being promoted by its P&G "competitor"
"While the multinational has thousands of its own product development staff, its Connect & Develop programme aims to develop half of new products and service ideas from partnerships with companies, individual inventors, and in some cases, even competitors." - Bob McDonald P&G CEO
Colgate Palmolive and Procter & Gamble are the largest players in the oral care business globally. Colgate is the world leader in oral care with a 33% market share, followed by P&G’s Crest and Oral-B brands, which together command 20% of the market. - Source
Note: Peak Research also released this report which stated, GSKCH is the second largest company in the field of dental care products worldwide
What Colgate have to say about its two largest competitors: Competition Situation Analysis
Aquafresh
Aquafresh was established in 1973, and is currently owned by GlaxoSmithKline Aquafresh is originally known for its tri-colored red, white and turquoise stripes. The Aquafresh product line has expanded into some unique features not offered by other toothpaste brands. The Aquafresh Extreme line uses micro-active foam to clean and smooth teeth over time, creating a deeper clean feeling among consumers. The Aquafresh ISO-Active products start as gel from a unique pressurized canister that turns into an “active foam” similar to shaving cream but retrofitted for toothpaste. Advanced White products are advertised to safely penetrate the tooth enamel to create greater whitening rather than potentially harmful and abrasive techniques to polish teeth. Also, Aquafresh advertises unique flavored toothpastes such as citrus mint and icy mint in Aquafresh Advanced as well as a children’s flavor bubblegum-mint. All of these features make Aquafresh a modern and competitive toothpaste brand.
Market
Aquafresh’s market share of 8.13% translates to $918,937,367 or 3.23% of the GSK net sales. Aquafresh’s market penetration is approximately 18.11%.
Price
Aquafresh had only nine product facings, none of which were eye level with the consumer. The subtotal of the product per ounce is $0.75 ranking in the middle between Crest (low) and Colgate (high).
Place/Promotion
Aquafresh can be found in the oral health isle at the following stores; Target, Walgreens, Walmart, Costco, CVS Pharmacy and Wegmans. Aquafresh can also be found online at these websites: Costco,com Drugstore.com and Amazon.com. Aquafresh has a comprehensive promotions campaign using outdoor, print and television created by MediaCom. The online design of the Aquafresh website is modern and easily navigable.
Strengths and Weakness Analysis
Strengths: Aquafresh uses innovative oral health technologies to appeal to a younger audience. The packaging of Aquafresh Extreme Clean is a shimmering, glittery box that appears hip and current. This along with low product facings is a marketing ploy to appeal to children whose eye level is lower than adults. Aquafresh is priced in the middle of the toothpaste market in order to appeal to consumers.
Weakness: Aquafresh is a strong brand owned by the world's third largest pharmaceutical company. While the Aquafresh original is instantly recognizable by its distinct red, white and blue ribbon, other newer products are not as known. Aquafresh shelf facings are weak. Aquafresh products are usually displayed on the shelf below the consumers’ waistline. Compared with Crest and Colgate, Aquafresh has fewer facings in stores. Aquafresh appeals to a younger demographic leaving out older, higher spending consumers.
Crest
Crest appeared on the market in 1950 with a revolutionary cavity preventative product created by Proctor and Gamble. The classic Crest product line consists of a classic mint flavor in both gel and paste form. This toothpaste addresses the issue of fresh
breath and cavity prevention in weak areas. Beyond the classic line, Crest has expanded to 40 plus individual toothpastes. This allows Crest to appeal to a broader market than most other toothpastes. Crest created many innovations over the past 60 years, including a vast amount of creative flavorings in both gel and paste form such as: Cinnamon Rush, Refreshing Vanilla Mint, Burstin’ Bubblegum, Scope Minty Fresh, Herbal mint and Citrus Splash. Crest also has the widest variety of children’s toothpaste. These kid’s toothpastes come in gel form and feature famous children’s characters. For instance, Barbie toothpaste come in Burstin’ Bubblegum flavor and Crest Kid’s Spider-Man Liquid with Super Action Mint flavor.
In 2004, Crest introduced a higher quality, dentist inspired toothpaste product line called Crest Pro-Health. Crest Pro-Health is the only toothpaste accepted by the American Dental Association for six different areas: cavities, gingivitis, plaque, whitening, sensitivity, and bad breath.
Market
Proctor & Gamble has been producing household goods, health and well being, as well as, beauty and grooming products for over 179 years. P&G is the parent company of such brands as Tide, Bounty, Febreze, Gillette and Crest. P&G’s estimated enterprise value is $20,935 million. Specifically, the market share for Crest in 2010 is 32%, which is equal to $1,029,757,700 in Net Sales. That is 8.95% of the P&G health care segment and only half of a percent of its overall net sales.
Price
Crest has 37 product facings at consumer eye level and preferred shelving areas. Crest is the category leader in product volume offered with 37 facings per store. Crest toothpaste is also the least expensive of the three major brands at $0.69 per ounce.
Promotion
Coupons are the largest form of promotion offered by the home product giant P&G. Coupons can be found online via the Crest and Oral-B e-newsletter. Sent out monthly, the e-mail newsletter includes updates, latest advances, new products and exclusive offers at P&G. Crest also sends out the P&G BrandSaver found in over 500 local Sunday newspapers nationally. This coupon booklet provides discounts on P&G products that are redeemable at purchase.
Place
Crest toothpaste products can be found in the oral health isle of the following stores: Target, Walmart, Kmart, Dominicks, Sam’s Club, Walgreens, Meijer, Jewel Osco and CVS. Crest toothpaste can also be found at Amazon.com, Drugstore.com CVS.com Walgreens.com and Soap.com.
Strength and Weakness Analysis
Strengths: Crest, owned by Proctor and Gamble, is a huge company. It is thirteen times the size of Colgate-Palmolive. P&G has more available capital and over all presence throughout the market place. Crest spent $1.3 billion over the last 5 years on advertising. Based upon market research, Crest out ranks other brands in taste
preference. Crest has the most product facings in a given store and cheapest overall price per ounce.
Weakness: Proctor and Gamble is a huge company where Crest makes up a very small percentage of the total sales of the company. Therefore, it would seem that Crest products are given a large marketing budget but lack the proper care and attention needed to foster consumers and market share. Crest goes against the current and past trend by offering more gel than most other toothpaste companies. Crest spends an incredible amount on advertising but their market penetration is only equal to 62% of the market place. - Colgate Marketing Plan - Competition Situation Analysis
The following information highlights the importance of DYOR, as well as what I refer to as the 'sum of all things' in regards to having a better understanding of the company's three part development strategy, especially when refering to OBJ's "own products" development group - This should not be interpreted as a, "going-it-alone" strategy.
The following email response was kindly shared in Post: 8406285 back in August by greenhouse on 13/08/2012:
Q: Im a shareholder of Obj Limited and have found a Job advertisement for Obj limited, after reading the advertisement im just wondering what the highlited phrase means or who it refers too?
"The products are currently being developed by one of the world’s leading transdermal drug delivery companies in conjunction with international sports medical and formulation experts. The unique selling features and benefits provided by the Australian developed transdermal technology will provide new levels of features, functions and performance beyond the capabilities of existing competitor products."
Glyn's reply: We are presently in the process of drafting an update and when we have received approval from our various partners (where this is required) we will so advise the market.
Here's the first paragraph of the position posted by OBJ Limited on Seek.com in July this year, which greenhouse was refering to in his email to the company...
Australia's leading transdermal patch development company seeks an experienced and motivated Market Development Manager to lead the final development stages and manage the international roll-out of a unique platform of sports and consumer pain and injury management products. This new platform of sports and retail medical products will create a new category in the international professional and amateur sports medicine, rehabilitation and injury treatment markets.
The relevance to this information is in two parts:
1. Glyn's reply didn't answer the question greenhouse raised in regards to the information in the job placement for someone to manage OBJ's 'own products' development program, and nor did this Shareholder Update released to the market two days later.
2. What Glyn did offer in response to greenhouse's question about the company's 'own products' development programs, was this:
"when we have received approval from our various partners (where this is required) we will so advise the market"
In my honest and informed opinion if greenhouse had asked that same question about 12 months before that job position was posted, he would've received a less guarded response...
"This new development program is significant as we are targeting a particular application and the team at OBJ will learn a great deal with regard to the manufacturability of the patch and of how the patch is applied to the human body. This experience of course will not be very useful to the other development programs with our partnering companies. But the development itself will go through all of the phases necessary to properly develop a product and the Board may elect at any stage to bring in partners if we so need. That option is always open to us."
________________________________________
Financial Resources
Finally, it's important to know whether the company is well-financed. After all, funding is the fuel of the biotech industry. Without funding, a biotech company will be forced to cut back on R&D, and clinical and commercial activities – reducing its chances of maximizing return on investment. It's reassuring to see enough cash on the balance sheet to cover expenses for at least a year or two. A solid cash position means that the company can strike up favorable partnerships without having to accept the first deal on offer. Of course, the hope is that the biotech company won't have to rely on external financing and cash reserves to keep R&D and commercial development going and will eventually be able to run profitably from high margin revenues. - Source
Sep 2012 - $3,292,000
Jun 2012 - $3,696,000
Mar 2012 - $3,732,000
Dec 2011 - $3,827,999
The cash burn rate is always an important management measure becaused combined with available funds, it provides a reasonably reliable time measure for when the next capital raising event may need to take place. At the current cash burn rate reported by OBJ over the past 12 months the picture, as compared to other listed biotech specs continues to show great management of company finances - one which would normally establish we have another 6.2 years left in the bank.
However, many here continue to speculate, (myself included) that whilst management have also highlighted its “Own Products” development group responsible for the creation of OBJ’s own products utilising the Company’s proprietary technologies, they may be on the cusp of one or more material deals which could have a significant impact on financial Resources.
It should also be noted that the Company have a mandate to issue securities under the additional 10% placement facility from the date of the AGM until the earlier of the following to occur:
a) the date that is 12 months after the date of the Annual General Meeting; and
b) the date of the approval by Shareholders of a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking), (the Additional 10% Placement Period).
________________________________________
The Bottom Line
It's almost impossible for the average investor to grasp the science that underlies biotech companies and their development projects. Given that biotech businesses typically have scant financial records, quantitative analysis represents a big challenge for investors, too. That said, looking at the key qualitative drivers of biotech value – namely a promising product pipeline, patents, good management, durable partnerships and access to funds – offers a good first step in sizing up biotech potential. - Source
"seeking world-wide exclusive access rights to OBJ’s technologies"
"in discussions with five of the world’s largest Consumer Healthcare companies across a variety of applications"
"the fast moving consumer goods company would be granted a licence for each product and receive royalties for five years or life of patent, whichever was longer."
"working closely with two of the world's foremost cosmetic brands"
"significant expansion to IP and Patent portfolios with applications covering the commercial areas of interest to OBJs partner companies"
"working with one of the worlds largest pharmaceutical companies in consumer acceptance testing for a patch version of an existing multi-billion dollar product currently sold internationally"
"This year was a very progressive one with significant developments across our core activities."
"The announcement of the JDA with P&G and the expansion of programs with GSK, were major accomplishments for the period."
"FMCG initial 5 year Strategic Alliance for the design and development of a wide range of consumer products"
"Global FMCG Company to Secure Access Rights"
"GSK has reported commercially and statistically significant levels of enhancement"
"commences multi-product discussions with major US Pharma"
"3M remains a major collaborator with OBJ"
Today, I would propose we add one additional item for consideration when conducting qualitative analysis as a method for putting a more reliable value on a biotech company...
Sustainability
It would be impossible for any person to provide an argument denying the level of interest for OBJ's technology offerings when citing the global names they are working with. Global corporations like GSK and P&G are both known for their pursuit of 'outside' innovative science which will significantly impact medical care - And both of these giants are only interested in working with the best scientific minds, and most promising technology platforms with a solid scientific foundation.
Imo, our market's failure to recognise true innovation with the real potential of providing solutions to promote a environmentally sustainable future for our planet, may largely be attributed to our own government's intimate love affair with its poluting ambitious commitment to funding fossil fuels. Australia have now stolen the top honors for the highest ratio of fossil fuel subsidies compared to climate finance from the US. (with thanks to the Australian tax payer)
Australian listed company CFU have developed and commercialised, BlueGen® - the world's most efficient small-scale generator
The following abstract from the Ceramic Fuel Cells Chairman's address at CFU's AGM exposes our government for what they really stand for;
To be clear – we are not talking about Government cash handouts or massively over-generous premium feed-in tariffs, which some other technologies have received. We believe support is justified by our ability to generate electricity at double the efficiency of coal generators and our delivery of three times the carbon savings of the average home solar PV unit. Importantly, because we generate electricity where it is actually consumed, there is no investment needed for new transmission lines.
In the absence of political progress in Australia, we are fortunate to be able to focus on those international markets where the policies are already in place to support us. Markets such as Germany, the UK and The Netherlands, welcome our technology and as very large markets we are focussing our attention there.
It's quite sad when we consider that if the Australian developer of the world's most efficient small-scale generator wasn't supported by those European nations, the company would not have survived to this day.
Australia is responsible directly and indirectly for over 1.5 billion tonnes of CO2 per year – more than Germany’s emissions (population 82 million) and the UK’s emissions (population 62 million) combined. The international declarations – to which Australia is a signatory – state that parties “have the responsibility to ensure that activities within their jurisdiction or control do not cause damage to the environment of other States”. The greater our dependency on a coal/gas export economy, the greater the economic distortions and social perils for Australia in the longer term. Australia’s export energy boom is generating an economy unsustainably dependent on the returns of that sector. If the end to the fossil energy boom is abrupt, the trauma to Australia’s economy will be significant. Ultimately change will be forced upon us, whether or not we like it, or are prepared. Major importers are already moving to cap and reduce their coal consumption. Our export carbon sector is clearly unsustainable if the rest of the world intends to cut fossil fuel use dramatically. A coherent energy-climate policy would guide a rapid, planned scale-down in coal production. The chaotic alternative – the one we have now – will continue to build our coal export sector and then allow market and climate forces to combine in a perfect economic storm. - Why Australia must stop exporting coal
Thanks to funding provided by the CSIRO, Melbourne, Monash, RMIT, UTS, UWA, Canberra, CDU, Deakin, Flinders, Griffith, La Trobe, Murdoch, QUT, Swinburne, UniSA, USQ, UTAS, UWS and VU, articles like this from Prof Christoff at the University of Melbourne can keep the Australian public informed, but give a moments thought to Prof Christoff words...
Ultimately change will be forced upon us, whether or not we like it, or are prepared
How ironic it will be when global fossil fuel divestment movements like Bill McKibben's 350.org, as mentioned on this forum recently, which plan to target Australia's booming coal industry in 2013, are now attracting the support of some of the largest global corporations
The irony may be seen in the headlines in 2013 - 'Global Corporations take action to stop Australia's ALP and Greens Party from poluting the world!'
Seattle Mayor Calls For Divesting City Pension Funds From Fossil Fuels
Dec 23, 2012
After a 21-city tour educating people on a new fossil fuel divestment campaign, climate activists are starting to see results.
In the last month, groups on 192 university and college campuses have organized campaigns to pull their schools’ endowments out of the fossil fuel industry. One small school, Unity College, has already committed to divesting from coal, oil, and gas. At Harvard, a school with the country’s largest endowment, 72 percent of students voted in favor of divesting from fossil fuels. Although Harvard officials balked, a group of student activists has kept the pressure on.
There’s another big piece of news on the divestment front this week. Seattle Mayor Mike McGinn is now calling on his city to strip fossil fuels from its two main pension funds. Mayor McGinn sent a letter to the city’s pension fund managers on Friday calling for them to move their money elsewhere:
To the members of the Seattle City Employees’ Retirement System Board:
"I write to you today to ask that you refrain from future investments in fossil fuel companies and begin the process of divesting our pension portfolio from those companies. I recognize that this process will require a thorough evaluation of the portfolio’s performance, assets, and investment strategies. City staff stand ready to assist you in this work. Climate change is one of the most important challenges we currently face as a city and as a society. We have watched in recent weeks as weather influenced by climate change has caused significant damage and financial losses to cities and states on the East Coast. The projections suggest that the problem could get much worse. According to Bill McKibben and 350.org, fossil fuel corporations now have 2,795 gigatons of carbon dioxide in their reserves, five times the amount considered safe to avoid catastrophic climate change". - Seattle Mayor Calls For Divesting City Pension Funds From Fossil Fuels
As Bill McKibben’s Do The Math tour sells out venues across the country, the call for divestment spreads nationwide
Over 100 campuses across the country have joined a new campaign from 350.org calling on colleges and universities to divest their endowments, estimated at a total of $400 billion nationwide, from the fossil fuel industry. The new campaign is being sparked by Bill McKibben and 350.org’s “Do The Math” tour, an effort to connect the dots between extreme weather, climate change, and the fossil fuel industry. The 21-city tour kicked off on November 7 in Seattle and has sold out every venue it’s visited.
“We’ve felt serious momentum along this transcontinental roadshow — but the numbers of full-on divestment campaigns got larger faster than we could have dreamed,” said McKibben.
The Go Fossil Free campaign is specifically calling for institutions to immediately freeze new investments in the 200 corporations that hold the vast majority of the world’s fossil fuel reserves and divest within five years from direct ownership and from any commingled funds that include fossil-fuel public equities and corporate bonds.
The effort has scored a number of early victories. At the Do the Math tour stop in Seattle, the Mayor committed to studying how the city could divest from fossil fuels. Just days later, Unity College in Maine announced that it would divest its entire endowment from fossil fuels. - Source
Q: Why are some of the world's largest global corporations supporting these anti fossil fuel campaigns?
The GSK-Singapore Partnership for Green and Sustainable Manufacturing
Sustainability at 3M
P&G - 2012 Sustainability Report
Environmental Sustainability: Pfizer Is on a Green Journey
Samsung - Climate Strategy
2013 Global Life Sciences Outlook
Answer: Nations like Australia which are being run by the ALP and Greens, and whose actions are clearly in support of increasing our fossil fuel industry to add further polution in our planet, are also responsible for stalling innovation, and this my friends, becomes a significant threat to our global partners bottom line!
"OBJ is the first company in the world to develop low cost micro-array film technology that utilizes diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of commercially significant drugs and peptides used in the pharmaceutical, dermatology, cosmetic and consumer healthcare sectors. Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins, vaccines, antibodies and anti aging molecules has long been the desire of the pharmaceutical industry. It would provide economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Side effects could be reduced by localised delivery and programmed delivery rates. Needle stick injuries and needle disposable problems could be eliminated while the reduction in the level of skill required for application could significantly reduce total cost of many health programmes.
"OBJ’s technologies are unique in that they utilise the interaction forces generated between molecules and magnetic fields to change the way molecules move into or through the skin and hair follicles. By utilising physical science rather than chemistry, OBJ is able to provide its international partners with cost-effective means of enhancing the performance of a wide range of therapeutic, applications, often to levels not possible using costly formulation chemistry."
"New therapies that fuse physics, electronics, biology and medicine may upend how the industry thinks about treatment. “Rather than loading the body with drugs with potentially deleterious effects, we’ll have the ability to execute pinpoint interventions using electrons,” - John Baldoni - GSK
"True innovation is becoming increasingly rare with regulatory barriers and increasing costs leading to more standardised products. OBJ’s physical rather than chemical approach to product performance enhancement may change the balance in established product categories" - Former manager of new technology and partnership licensing for Reckitt Benckiser, Unilever, and GSK - Dr Kevin Hammond
"GSK and OBJ have collaborated on enhanced oral healthcare developments on similar bases resulting in statistically and commercially significant levels of enhancement." - statement issued by GlaxoSmithKline Consumer Healthcare
"P&G’s partnership with OBJ and our joint commitment of collaboration directly aligns with P&G’s business strategies, working to develop new solutions and innovations that can touch and improve the lives of our consumers all over the world," - P&G Vice President of Global Business Development - Jeff Weedman
"I would have thought that anyone would see that this is a considerable volume of activity that has steadily been building over many years and we remain optimistic that some of these opportunities may progress to further stages as we go through the product development and commercialisation cycle. It really is a tremendous range of opportunities." - Glyn Denison
"OBJ’s technologies are based on physical performance enhancement rather than chemical, and while this offers our products and patents a new way of approaching problems, the relative performance gains provided by technologies can outstrip anything available through formulation chemistry alone..."
John Baldoni, Ph.D., SVP platform technology and science R&D with GSK, discussed knowledge as becoming a commodity, and he predicts the next therapeutic game changer will come not from drugs, but electrons.
OBJ patent abstract
An apparatus for facilitating transdermal delivery of therapeutic substances, said apparatus comprising: an electromagnetic field generating device including a solid state switching device coupled to a coil which has electrical connectivity at both ends to allow unidirectional flow of current, the solid state switching device being operative to energize the coil with direct current to selectively produce an electromagnetic field; a control device coupled to the solid state switching device to control said field generating device to alternately produce active and substantially inactive electromagnetic field portions by selectively energizing the coil, each said active electromagnetic field portion having a frequency of between 1 Hz and 100 Hz and comprising a plurality of generally rectangularly-shaped electromagnetic field pulses wherein each electromagnetic field pulse has a duration of between 25 .mu.s and 100 ms, each said substantially inactive electromagnetic field portion including no electromagnetic field pulses, wherein the duration of the inactive electromagnetic field portion is longer than the duration of the active electromagnetic field portion.
P&G CEO Bob McDonald - Earnings Call Transcript August 2012
________________________________________
Some additional links to information sourced for this post
Generics rise sparks delivery tech need; Interphex speaker
Technical Program - IEEE MEMS 2012 Conference
P&G - 2012 Annual Report
Valuing biotech stocks
Investopedia: How To Do Qualitative Analysis On Biotech Companies
The World's Top 50 Consumer Products Companies - Joining The Dots
Changing the Conversation about Cancer 2012
Hidden Heroes: The Next Generation of Retail Markets
obj - qualitative analysis 2013
-
Share
-
- There are more pages in this discussion • 218 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
| WFL (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online